1884.9000 -15.10 (-0.79%)
NSE Nov 20, 2026 15:31 PM
Volume: 1.9M
 

1884.90
-0.79%
Emkay
Sun’s Organon acquisition marks a clear departure from its recent acquisition template – multiple sub-USD500mn assets over the years vs adding a company of its own scale as part of a single acquisition.
Sun Pharmaceutical I.. has an average target of 2077.88 from 8 brokers.
More from Sun Pharmaceutical Industries Ltd.
Recommended